On January 6, 2021 Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, reported Helen Sabzevari, PhD, President and CEO of Precigen, will present a corporate and clinical overview at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 3:40 PM ET (Press release, Precigen, JAN 6, 2021, View Source [SID1234573565]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Sabzevari will also participate in a panel discussion hosted by Scott Gottlieb, MD, at the H.C. Wainwright BioConnect 2021 Conference on January 13, 2021 at 12:00 PM ET. The panel will explore precision medicine and the importance of biomarkers and cytogenetic profiling in drug discovery, development and commercialization.

Participants may access the live webcasts of the virtual events through Precigen’s website in the Events & Presentations section at investors.precigen.com/events-presentations.